Dermatology

Misha Rosenbach, MD, gives an overview of climate change and its relevance to dermatology.

Meaningful change thresholds in POEM and DLQI scores have been established for adolescents and adults.

There may be an association between atopic dermatitis severity and diagnosis of ocular disease, such as conjunctivitis.

Secukinumab is the only fully human biologic that directly inhibits IL-17A.

Misha Rosenbach, MD, discusses how rising temperatures and climate change, issues of public health concern, are relevant to the field of dermatology.

In both studies, a higher proportion of patients on upadacitinib 15 mg and 30 mg achieved EASI-75, EASI-90, and EASI-100 compared with the placebo groups.

Internet-delivered CBT may be an efficient and convenient means for addressing behaviors that exacerbate atopic dermatitis-related symptoms.

Patients treated with ruxolitnib cream show ≥75% improvement in facial vitiligo scoring index.

Patients who received 2 mg or 4 mg of baricitinib maintained vIGA-AD scores through 68 weeks of treatment.

A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

Esther Freeman, MD, PhD, discusses the most frequent cutaneous presentations associated with vaccination.

A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.

An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.

A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

All patients treated with 2.5 benzoyl peroxide and a stabilized cosmetic retinol saw significant improvement in lesion count reduction after 12 weeks.

Implementing alternative therapies does not mean abandoning conventional medications, stresses Peter Lio, MD. There must be a balance that works for the patient's situation.

Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.

Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.

New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.

The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.

Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.